NLTX - Neoleukin: New Phase 1 Initiation Strong Managerial Expertise And Promising Technology

• Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-protein design.
• Neoleukin is developing one clinical therapeutic, NL-201 which is an IND-Phase 1 IL-2/IL-15 immunotherapy being studied for relapsed or refractory solid tumors, a projected $183B market.
• Neoleukin is in a strong position after the 3Q capital raise which brought the basis of their cash + short term investments to $201M. Under the company's estimates, this will fund operations to 2023.
• Neoleukin has 3 key catalysts for 2021: the initiation of NL-201's Phase 1 for solid tumors, the awaited second therapeutic program's IND enabling study, and late 2021 NL-201's Phase 1 data release.
• In summary, the author projects Neoleukin Therapeutics as a "buy" at a 5-7 year price target of $51 (+289% upside).

For further details see: